6月15日 - ** 生物技术公司Elicio Therapeutics（ELTX.O）的股价在盘前交易中暴跌50%，至7.43美元
** 该公司表示正在胰腺癌患者中进行测试的实验性疫苗ELI-0027P未能预防疾病复发
** ELTX称，该中期研究对144名接受过手术和标准治疗的患者进行了测试
** 称肿瘤完全切除的亚组患者癌症复发风险降低了35%
** 胰腺癌因常被晚期诊断且对现有疗法反应不佳，治疗难度较大
** 公司称该疫苗诱发的免疫反应与更好的治疗结果相关
** ELTX计划开展针对该亚组且治疗周期更长的晚期研究
** 截至上一交易日收盘，该公司股价年内累计上涨约87%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.